Hoe verhoudt CBAY's PB Ratio zich tot zijn concurrenten?

CBAY is duur op basis van de Price-To-Book -ratio ( 12.8 x) vergeleken met het gemiddelde van de peer ( 9 x).

Hoe verhoudt CBAY's PB Ratio zich tot andere bedrijven in de US Pharmaceuticals industrie?

CBAY is duur op basis van de Price-To-Book -ratio ( 12.8 x) vergeleken met het US Pharmaceuticals -industriegemiddelde ( 1.7 x).

Wat is CBAY's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { CBAY te berekenen voor waarderinganalyse.

Wat is de reële prijs van CBAY als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

CBAY ( $32.48 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $247.34 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

CymaBay Therapeutics (Nasdaq:CBAY) - Aandelenkoers, Nieuws & Analyse

CBAY Overzicht aandelen

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Meer informatie

CBAY fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 86.9% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 50.87% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

CymaBay Therapeutics, Inc. Concurrenten

Avadel Pharmaceuticals

NasdaqGM:AVDL

US$1.0b

Axsome Therapeutics

NasdaqGM:AXSM

US$4.6b

Nuvation Bio

NYSE:NUVB

US$868.3m

CorMedix

NasdaqGM:CRMD

US$651.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor CymaBay Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$32.48
52 Week Hoogtepunt	US$32.50
52 Week Laag	US$7.26
Bèta	0.32
11 maand verandering	0.87%
3 maanden verandering	40.67%
1 Jaar Verandering	262.91%
33 jaar verandering	607.63%
5 jaar verandering	147.94%
Verandering sinds IPO	260.89%

Recent nieuws en updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Rendement voor aandeelhouders

	CBAY	US Pharmaceuticals	US Markt
7D	0.03%	-1.4%	0.3%
1Y	262.9%	10.8%	31.1%

Rendement versus industrie: CBAY overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 10.8 % opleverde.

Rendement versus markt: CBAY overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is CBAY's price volatile compared to industry and market?
CBAY volatility
CBAY Average Weekly Movement	8.2%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van CBAY is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van CBAY is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1988	101	Sujal Shah	www.cymabay.com

CymaBay Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van CymaBay Therapeutics zich tot de beurswaarde?
CBAY fundamentele statistieken
Marktkapitalisatie	US$3.73b
Inkomsten(TTM)	-US$105.37m
Inkomsten(TTM)	US$31.07m

120.0x

P/S-verhouding

-35.4x

Koers/Winstverhouding

Is CBAY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CBAY resultatenrekening (TTM)
Inkomsten	US$31.07m
Kosten van inkomsten	US$80.80m
Brutowinst	-US$49.73m
Overige uitgaven	US$55.64m
Inkomsten	-US$105.37m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.92
Brutomarge	-160.03%
Nettowinstmarge	-339.10%
Schuld/Eigen Vermogen Verhouding	37.4%

Hoe presteerde CBAY op de lange termijn?

Bekijk historische prestaties en vergelijking

CBAY Overzicht aandelen

Beloningen

Risicoanalyse

CymaBay Therapeutics, Inc. Concurrenten

NasdaqGM:AVDL

US$1.0b

NasdaqGM:AXSM

US$4.6b

NYSE:NUVB

US$868.3m

NasdaqGM:CRMD

US$651.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?